Skip to content
CharitiesAidWelfare, Medical Health Aged Care

Blood Cancer Taskforce unveils new Optimal Care Pathways for blood cancer treatment and care

Blood Cancer Taskforce 3 mins read
Blood Cancer Taskforce

Australia’s Blood Cancer Taskforce today released five new Optimal Care Pathways (OCPs), marking a significant advancement for blood cancer treatment and care in Australia.


The OCPs are trusted guides that describe what optimal care for a particular type of cancer should look like, while putting patients at the centre of care decisions. They also help set the national standard of high-quality care, which is critically important for the 140,000 Australians currently living with blood cancer.


The five new OCPs will join the existing eight blood cancer OCPs, including six that were previously developed by the Blood Cancer Taskforce in 2022 - jointly led by the Australasian Leukaemia & Lymphoma Group (ALLG) and the Haematology Society of Australia and New Zealand (HSANZ) - and two that were developed by the Cancer Council in 2021.


Chris Tanti, Co-Chair of the Blood Cancer Taskforce and Leukaemia Foundation CEO emphasised the importance of the OCPs and said that they are a vital blueprint for delivering the highest standard of care and treatment at every stage of a patient’s journey.  


“The OCPs define the optimal care for someone diagnosed with a specific type of blood cancer and include a full OCP technical document specifically created for healthcare professionals,” said Mr Tanti.


“As well as assisting blood cancer specialists, the OCPs will also prove valuable for treating hospitals and GPs, ensuring they have access to the same information.


“The introduction of these new OCPs aim to reduce the variability in treatment and care across the country for each of these blood cancers, representing a milestone in the battle against blood cancer in Australia.


“We encourage healthcare professionals, along with patients and their loved ones, to access the OCPs to help them build an even better understanding of what the optimal care journey for a patient's particular type of blood cancer looks like.”


In addition to the technical document for healthcare professionals, the OCPs contain a short reference guide which acts as a companion document to the full optimal care pathway, and a guide specifically designed to help patients understand best cancer care.


They’ve been developed by Australia’s leading blood cancer treatment and care experts including the Haematology Society of Australia and New Zealand (HSANZ), together with patient representatives, and approved and endorsed by the Australian and State and Territory Governments. The blood cancers covered in these new OCPs are:


  1. Acute lymphoblastic leukaemia (ALL) – led by Dr Shaun Fleming and Dr Caroline McNamara
  2. AL-amyloidosis – led by Dr Fiona Kwok and A/Prof Peter Mollee
  3. Cutaneous T-cell lymphoma (CTCL) – led by Dr Dejan Radeski and Dr Carrie van der Weyden
  4. Myeloproliferative neoplasms (MPN) – led by Prof Steven Lane and A/Prof Kate Burbury
  5. Waldenström’s macroglobulinaemia (WM) led by Prof Judith Trotman and Dr Nicole Wong Doo 

The OCPs were led by a steering committee, Chaired by Dr Hui-Peng Lee, Clinical & Laboratory Haematologist and President of HSANZ.


Professor John Seymour AM, Co-Chair of the Blood Cancer Taskforce and Director of Clinical Haematology at the Peter MacCallum Cancer Centre and Royal Melbourne Hospital further highlighted how the OCPs support optimal care delivery.


“These OCPs have been developed through a collaborative, evidence-based process to guide healthcare professionals in providing consistent, effective treatment and support to blood cancer patients, regardless of where they live,” said Professor Seymour.


“We know that twenty-nine per cent of blood cancer deaths in this country could be avoided through the consistent delivery of the known national standards of timely and accurate diagnosis, optimal treatment, and care, and that’s significant.


“Australia has a world class health system and these new OCPs, along with the existing eight will ensure we now have Australian-specific standard frameworks for diagnosis, treatment, and care.”


Blood cancer is the second highest cause of cancer related deaths in Australia, with the development and endorsement of the OCPs forming part of an ongoing effort to improve survival rates and quality of life for blood cancer patients.


OCPs are one of the key recommendations in the Blood Cancer Taskforce’s National Strategic Action Plan for Blood Cancer (National Action Plan) which is a blueprint for change in the lives of people living with blood cancer. 


Integrating OCPs as routine cancer care is a key action within the Australian Cancer Plan’s strategic objective of achieving world class health systems for optimal care.


All versions of blood cancer specific OCPs are available to download from the Cancer Council website.


- END -


Available for interview:


  • Tim Murphy, General Manager Blood Cancer Partnerships, Leukaemia Foundation 
  • John Seymour, Co-Chair of the Blood Cancer Taskforce and Director of Clinical Haematology at the Peter MacCallum Cancer Centre & Royal Melbourne Hospital

Contact details:

For all media enquiries please email


More from this category

  • Medical Health Aged Care
  • 24/06/2024
  • 17:07
Takeda Pharmaceutical Company Limited

Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies

LIVTENCITY Is the First and Only Post-Transplant Anti-CMV Treatment Approved in Japan That Targets/Inhibits UL97 Protein Kinase1 CMV Is One of the Most Common…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 24/06/2024
  • 16:20
National Rural Health Alliance

Community-led innovation to revolutionise healthcare access in rural Australia

The National Rural Health Alliance (the Alliance) is delighted that the Minister for Health and Aged Care, the Hon Mark Butler, has today announced…

  • Contains:
  • Business Company News, Medical Health Aged Care
  • 24/06/2024
  • 12:25
Jane Morgan Management

Imugene (ASX:IMU) Doses First Patient in Pioneering Phase 1 onCARlytics Trial

Sydney, Australia, 24 June 2024: Imugene Limited (ASX: IMU), a clinical-stage immuno-oncology company, is thrilled to announce the dosing of the first patient in the intravenous (IV) infusion combination arm of its Phase 1 onCARlytics (CF33-CD19) clinical trial. This groundbreaking trial, named OASIS, is being conducted at City of Hope in California and is designed to transform the treatment landscape for patients with advanced solid tumors. The OASIS trial is a world-first, combining a CD19-expressing oncolytic virus with a CD19-targeting drug. The trial aims to recruit 40-45 patients with advanced solid cancers that have metastasized, with preliminary early combination data…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.